Tags & Categorías

Christophe Maupas: los biosimilares producirán en España «un ahorro de 2.000 millones»

Con motivo del lanzamiento al mercado en España de un nuevo medicamento biosimilar de la compañía farmacéutica Mylan, Acta Sanitaria ha entrevista...

Sandoz comercializará a nivel global su biosimilar para esclerosis múltiple

La compañía ha anunciado un acuerdo con Polpharma Biologics para su comercialización

National Health Service Reports Substantial Savings From Biosimilar Adalimumab

England’s National Health Service (NHS) says that it has saved £110 million (US $134 million) by implementing its policy to use the best-value ada...

Sandoz will appeal District Court of New Jersey ruling in biosimilar Erelzi® (etanercept-szzs) US pa...

Sandoz, a Novartis division and a global leader in biosimilars, today announced that the United States District Court of New Jersey ruled against Sand...

Ahead of Biosimilar Competition, Ranibizumab Gets a Positive CHMP Opinion for New Indication

Novartis, developer of the brand-name Lucentis, announced on Friday that the European Medicines Agency’s Committee for Medicinal Products for Human ...

Sandoz Enrolls First Patient in Study of Proposed Denosumab Biosimilar, GP2411

Sandoz announced today that it has enrolled its first patient in a combined phase 1 and phase 3 study of its proposed denosumab biosimilar versus EU-a...

EMA to Review Samsung Bioepis' Bevacizumab Biosimilar, SB8

Samsung Bioepis has announced that the European Medicines Agency (EMA) has accepted for review its market authorization application for SB8, a propose...

¿Qué barreras impiden la llegada de una oleada de biosimilares al mercado?

Los productores de biosimilares consideran que hay demasiados obstáculos hasta que logran comercializarlos

Biosimilares: la evolución del mercado será "más compleja" que en genéricos

El presidente de BioSim señala que médicos, farmacéuticos, administraciones y pacientes serán clave en su desarrollo.